Table 2 Antimicrobial susceptibility of Haemophilus species from patients with pneumonia. Comparison of antimicrobial susceptibility between CLSI 2004–2011 and EUCAST 2012–2014 criteria
|  |  |  | Number of patients with Haemophilus species = 82 |  |  |  |  | ||
|---|---|---|---|---|---|---|---|---|---|
Drug groups | Active substance | No. using antibiotics (%) | No. of antibiotic tests on antibiogram (%) | Sensitive (%) | Inter-mediate (%) | Resistant (%) | P value compared with Ampicillin + Sulbactam | P value compared with Ciprofloxacin | P value CAP compared to NAP |
Penicillins | Ampicillin | 1 (1.2) | 82 (100) | 61 (74.4) | 1 (1.2) | 20 (24.4) | 0.011 | <0.0001 | Â |
|  |  CAP | 0 | 53 (100) | 38 (71.7) | 1 (1.9) | 14 (26.4) | 0.010 | <0.0001 | 0.730 |
|  |  NAP | 1 (3.8) | 26 (100) | 20 (76.9) | 0 | 6 (23.1) | 0.066 | <0.0001 | 0.730 |
|  |  CLSI | 1 (2.9) | 34 (100) | 24 (70.6) | 1 (2.9) | 9 (26.5) | 0.019 | <0.0001 |  |
|  |  EUCAST | 0 | 48 (100) | 38 (79.2) | 0 | 11 (22.9) | 0.028 | <0.0001 |  |
| Â | Piperacillin | 1 (1.2) | 24 (29.3) | 19 (79.2) | 0 | 5 (20.8) | 0.128 | 0.0001 | Â |
|  |  CAP | 1 (1.9) | 12 (22.6) | 8 (66.7) | 0 | 4 (33.3) | 0.022 | <0.0001 | 0.430 |
|  |  NAP | 0 | 10 (38.5) | 9 (90.0) | 0 | 1 (10.0) | 0.848 | 0.0167 | 0.430 |
|  |  CLSI | 1 (2.9) | 24 (70.6) | 19 (79.2) | 0 | 5 (20.8) | 0.128 | 0.0001 |  |
|  |  EUCAST | 0 | 0 | 0 | 0 | 0 | 1.0 | 1.0 |  |
Penicillin + Beta- lactamase inhibitors | Ampicillin + Sulbactam | 28 (34.1) | 82 (100) | 74 (90.2) | 2 (2.4) | 6 (7.3) |  | 0.016 |  |
|  |  CAP | 23 (43.4) | 53 (100) | 47 (88.7) | 2 (3.8) | 4 (7.5) | 0.905 | 0.008 | 0.604 |
|  |  NAP | 4 (15.4) | 26 (100) | 24 (92.3) | 0 | 2 (7.7) | 0.723 | 0.042 | 0.604 |
|  |  CLSI | 12 (35.3) | 34 (100) | 29 (85.3) | 2 (5.9) | 3 (8.8) | 0.619 | 0.002 |  |
|  |  EUCAST | 16 (33.3) | 48 (100) | 45 (93.8) | 0 | 3 (6.3) | 0.533 | 0.075 |  |
|  | Piperacillin + Sulbactam | 8 (9.8) | 23 (28.0) | 22 (95.7) | 0 | 1 (4.3) | 0.651 | 0.169 |  |
|  |  CAP | 2 (3.8) | 11 (20.8) | 10 (90.9) | 0 | 1 (9.1) | 0.856 | 0.024 | 0.622 |
|  |  NAP | 4 (15.4) | 10 (38.5) | 10 (100) | 0 | 0 | 0.586 | 1.0 | 0.622 |
|  |  CLSI | 8 (23.5) | 23 (67.6) | 22 (95.7) | 0 | 1 (4.3) | 0.651 | 0.169 |  |
|  |  EUCAST | 0 | 0 | 0 | 0 | 0 | 1.0 | 1.0 |  |
|  | Piperacillin + Tazobactam | 24 (29.3) | 79 (96.3) | 77 (97.5) | 0 | 2 (2.5) | 0.135 | 0.354 |  |
|  |  CAP | 16 (30.2) | 51 (96.2) | 49 (96.1) | 0 | 2 (3.9) | 0.375 | 0.199 | 0.592 |
|  |  NAP | 8 (30.8) | 26 (100) | 26 (100) | 0 | 0 | 0.254 | 1.0 | 0.592 |
|  |  CLSI | 8 (23.5) | 31 (91.2) | 29 (93.5) | 0 | 2 (6.5) | 0.667 | 0.070 |  |
|  |  EUCAST | 16 (33.3) | 48 (100) | 48 (100) | 0 | 0 | 0.083 | 1.0 |  |
Cephalosporins | Cefuroxime | 3 (3.7) | 82 (100) | 73 (89.0) | 2 (2.4) | 7 (8.5) | 0.961 | 0.009 | Â |
|  |  CAP | 0 | 53 (100) | 46 (86.8) | 1 (1.9) | 6 (11.3) | 0.715 | 0.004 | 0.492 |
|  |  NAP | 3 (11.5) | 26 (100) | 24 (92.3) | 1 (3.8) | 1 (3.8) | 0.771 | 0.042 | 0.492 |
|  |  CLSI | 3 (8.8) | 34 (100) | 28 (82.4) | 1 (2.9) | 5 (14.7) | 0.454 | 0.0005 |  |
|  |  EUCAST | 0 | 48 (100) | 45 (93.8) | 1 (2.1) | 2 (4.2) | 0.760 | 0.075 |  |
| Â | Cefotaxime | 0 | 80 (97.6) | 78 (97.5) | 0 | 2 (2.5) | 0.13 | 0.359 | Â |
|  |  CAP | 0 | 52 (98.1) | 50 (96.2) | 0 | 2 (3.8) | 0.362 | 0.206 | 0.598 |
|  |  NAP | 0 | 26 (100) | 26 (100) | 0 | 0 | 0.254 | 1.0 | 0.598 |
|  |  CLSI | 0 | 32 (94.1) | 31 (96.9) | 0 | 1 (3.1) | 0.461 | 0.279 |  |
|  |  EUCAST | 0 | 48 (100) | 47 (97.9) | 0 | 1 (2.1) | 0.235 | 0.427 |  |
Gyrase inhibitors | Ciprofloxacin | 5 (6.1) | 81 (98.8) | 81 (100) | 0 | 0 | 0.016 | Â | Â |
|  |  CAP | 2 (3.8) | 52 (98.1) | 52 (100) | 0 | 0 | 0.067 | 1.0 | 1.0 |
|  |  NAP | 2 (7.7) | 26 (100) | 26 (100) | 0 | 0 | 0.254 | 1.0 | 1.0 |
|  |  CLSI | 2 (5.9) | 33 (97.1) | 33 (100) | 0 | 0 | 0.177 | 1.0 |  |
|  |  EUCAST | 3 (6.3) | 48 (100) | 48 (100) | 0 | 0 | 0.083 | 1.0 |  |
| Â | Levofloxacin | 4 (4.9) | 63 (76.8) | 62 (98.4) | 0 | 1 (1.6) | 0.121 | 0.525 | Â |
|  |  CAP | 4 (7.5) | 46 (86.8) | 46 (100) | 0 | 0 | 0.091 | 1.0 | 0.253 |
|  |  NAP | 0 | 17 (65.4) | 16 (94.1) | 0 | 1 (5.9) | 0.787 | 0.090 | 0.253 |
|  |  CLSI | 0 | 16 (47.1) | 16 (100) | 0 | 0 | 0.427 | 1.0 |  |
|  |  EUCAST | 4 (8.3) | 47 (97.9) | 46 (97.9) | 0 | 1 (2.1) | 0.244 | 0.419 |  |
Macrolide | Erythromycin | 0 | 81 (98.8) | 43 (53.1) | 7 (8.6) | 31 (38.3) | <0.0001 | <0.0001 | Â |
|  |  CAP | 1 (1.9) | 52 (98.1) | 27 (51.9) | 6 (11.5) | 19 (36.5) | <0.0001 | <0.0001 | 0.458 |
|  |  NAP | 0 | 26 (100) | 13 (50) | 1 (3.8) | 12 (46.2) | <0.0001 | <0.0001 | 0.458 |
|  |  CLSI | 1 (2.9) | 33 (97.1) | 24 (72.7) | 4 (12.1) | 5 (15.2) | 0.037 | <0.0001 |  |
|  |  EUCAST | 0 | 48 (100) | 19 (39.6) | 3 (6.3) | 26 (54.2) | <0.0001 | <0.0001 |  |